TFF Pharmaceuticals (NASDAQ:TFFP) reported quarterly losses of $(2.40) per share which missed the analyst consensus estimate of $(2.26) by 6.19 percent. The company reported quarterly sales of $203.27 thousand which beat the analyst consensus estimate of $75.00 thousand by 171.03 percent. This is a 295.25 percent increase over sales of $51.43 thousand the same period last year.
TFF Pharmaceuticals Q1 2024 GAAP EPS $(2.40) Misses $(2.26) Estimate, Sales $203.27K Beat $75.00K Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.